ABBV-8E12 + Placebo solution for IV infusion on Day 15
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Progressive Supranuclear Palsy (PSP)
Conditions
Progressive Supranuclear Palsy (PSP)
Trial Timeline
Jan 24, 2018 → Dec 13, 2019
NCT ID
NCT03391765About ABBV-8E12 + Placebo solution for IV infusion on Day 15
ABBV-8E12 + Placebo solution for IV infusion on Day 15 is a phase 2 stage product being developed by AbbVie for Progressive Supranuclear Palsy (PSP). The current trial status is terminated. This product is registered under clinical trial identifier NCT03391765. Target conditions include Progressive Supranuclear Palsy (PSP).
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03391765 | Phase 2 | Terminated |
Competing Products
20 competing products in Progressive Supranuclear Palsy (PSP)